Cell Freezing Market - Strategic Insights and Forecasts (2026-2031)

The Cell Freezing Market is expected to grow at a CAGR of 7.9%, reaching USD 477.4 million in 2031 from USD 302.6 million in 2025.

The cell freezing market is anticipated to grow at a steady pace throughout the forecast period. Cell freezing is a technique used to preserve cells at extremely low temperatures for long-term storage. The process involves cooling cells to very low temperatures, typically below -80 degrees Celsius, to slow down their metabolic activity and halt all cellular processes. There are several benefits of the cell freezing technique, which is driving the market growth. The rising prevalence of chronic diseases, along with the advancements in cell therapies are also expected to boost the cell freezing market. Moreover, the advancements in freezing technologies and governmental support are further contemplated to bolster the cell freezing market.

Cell Freezing Market Growth Drivers:

• Multiple Associated Advantages of Cell Freezing

Cell freezing offers several advantages that make it a valuable technique in various fields of research, medicine, and biotechnology. It allows cells to be stored for extended periods, ranging from months to years, without significant loss of viability or functionality. This long-term preservation ensures a stable and reliable supply of cells for research, clinical applications, and other purposes. It allows for the storage of therapeutic cells, such as stem cells and immune cells, which can be later thawed and used for transplantation into patients. It also reduces biological waste by allowing unused cells or tissues to be stored instead of being discarded. All these advantages related to cell freezing are accelerating the cell freezing market growth.

• Advancements in Cell Therapies

The field of regenerative medicine and cell-based therapies has been witnessing significant progress, which is driving the cell freezing market. Cell freezing is crucial for the successful development and deployment of cell therapies, including stem cell treatments such as CAR-T cell therapies, and other immunotherapies. The introduction of StemOne, an over-the-counter cell treatment product from Alkem Laboratories, was approved by the Drug Controller General of India (DCGI) in India in September 2022. A new firm called Abata Therapeutics was established in June 2021 with $95 million in series A investment to advance cell treatment. Abata's main focus is on treating later-stage, non-relapsing cases of multiple sclerosis.

• Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic and degenerative diseases fuels the demand for cell-based research and cell therapies. Consequently, this is also expected to boost the cell freezing market with a need to store cells for these applications. For instance, according to the WHO estimates, 17.9 million deaths worldwide in 2019 were attributable to cardiovascular diseases (CVDs), representing 32% of all fatalities. Moreover, chronic diseases account for more than 50% of all deaths in India, according to the Ministry of Science and Biotechnology. Additionally, in the United States, there are more than 100 million people who suffer from liver disease, according to the CDC data.

• Advancements in Cryoprotective Agents & Freezing Technologies

Continuous research and development efforts have led to the discovery of improved cryoprotective agents and freezing technologies that enhance cell survival rates during the freezing and thawing processes. These advancements boost the adoption of cell freezing methods across various applications, thereby propelling the cell freezing market. For instance, BlueCube Bio launched a new cell freezing technology for use in cell and gene therapies utilizing induced Pluripotent Stem Cells (iPSCS) in December 2021. It increases cell survival as compared to other available DMSO-based options in the market.

• Government and Institutional Support

Governments and research institutions worldwide are increasingly investing in life sciences research and biobanking initiatives. Supportive policies and funding for research in areas like regenerative medicine and stem cell research stimulate the cell freezing market. For instance, CryoLogyx, a spin-out company of the University of Warwick, received a £300,000 grant from Innovate UK in February 2021 to create novel cryopreservation agents with potential in the diagnostic, drug development, and cell-based treatment industries.

Cell Freezing Market Restraints:

The cell freezing market has experienced growth and development; however, some restraints or challenges can impact its expansion. For example, the use of cryoprotective agents is crucial for protecting cells during freezing, but some cryoprotectants, such as DMSO, can be toxic to cells at high concentrations. Moreover, cell freezing techniques often require specialized knowledge and expertise. Proper training and experience are necessary to ensure successful cell freezing and thawing processes, making it challenging for some researchers and institutions to implement cryopreservation protocols effectively.

Cell Freezing Market Geographical Outlook:

• North America is Expected to Grow Considerably

North America is expected to hold a significant share of the cell freezing market during the forecast period. The factors attributed to such a share are the presence of advanced healthcare facilities, earlier adoption of technology, increased government support, and the presence of major market layers such as Corning and BPS Bioscience. Moreover, the rising prevalence of chronic diseases and the growing elderly population is further driving the cell freezing market.  For instance, one in six Americans lives with at least one chronic disease, and these are also a leading driver of healthcare costs, according to the CDC's recent data.

List of Top Cell Freezing Companies:

• Sigma-Aldrich is a leading life science and high-technology company that provides a vast range of products and services to researchers, scientists, and businesses globally. It offers cell freezing medium, DMSO Serum Free 1x, which is suitable for cell culture and available in a 50ml pack size.

• Sartorius is a German-based company that was established in 1870. Sartorius specializes in bioprocessing solutions, including single-use technologies, filtration, purification, fermentation, and fluid management systems. It offers NutriFreez® and NutriStor® cold storage solutions for preservation of cells, including stem cells and T cells.

• AMSBIO is headquartered in Abingdon, United Kingdom, and operates as a subsidiary of Bio-Connect Life Sciences BV. The company serves researchers, scientists, and laboratories worldwide with its diverse product portfolio. CELLBANKER® freezing media is developed by the company that offers high cell viability in serum, serum-free, GMP, and DMSO-free formats.

Cell Freezing Market Developments:

• July 2025: BioLife Solutions invested convertible notes in Pluristyx, Inc., continuing strategic support of induced pluripotent stem cell (iPSC)-related cryopreservation developments in cell therapy workflows.

• April 2025: BioLife Solutions completed the acquisition of PanTHERA CryoSolutions to enhance its biopreservation portfolio with Ice Recrystallization Inhibitor (IRI) cryopreservation technology for superior freezing outcomes.

• March 2025: Alpha Teknova and Pluristyx launched the proprietary PluriFreeze™ cryopreservation system, a synthetic, animal-origin-free cell wash and freezing medium combo designed to streamline cryopreservation for allogeneic cell therapies.

Cell Freezing Market Scope: